Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-020-03476-4
Abstract: Crizotinib is the first-line small molecule tyrosine kinase inhibitor for ALK-positive non-small cell lung cancer. In this study, a retrospective pharmacogenomics investigation was conducted to explore the relationship between genes related to RTK downstream signaling… read more here.
Keywords: crizotinib; alk positive; toxicity; crizotinib induced ... See more keywords